Akero Therapeutics, INC Form 4 insider transactions

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, executed pre-planned stock option exercises and subsequent share sales on September 8, 2025.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, executed a pre-planned transaction, exercising stock options and selling an equal number of common shares.

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, exercised stock options to acquire 2,600 shares of common stock at $19.62 per share, increasing his direct beneficial ownership.

Akero Therapeutics' COO, Jonathan Young, exercised stock options and subsequently sold a portion of his shares for a significant gain under a pre-arranged trading plan.

Akero Therapeutics President and CEO Andrew Cheng sold 29,000 shares of common stock for approximately $1.46 million through a pre-arranged 10b5-1 trading plan.

Akero Therapeutics Director Jane Henderson exercised stock options and subsequently sold 3,000 shares of common stock for a significant gain.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and subsequently sold a portion of the acquired shares under a pre-arranged 10b5-1 trading plan.

Akero Therapeutics, Inc.'s Chief Development Officer, Catriona Yale, completed a pre-scheduled exercise of stock options and subsequent sale of common stock, realizing a significant gain.

Akero Therapeutics, Inc. President and CEO Andrew Cheng sold 30,000 shares of common stock for approximately $1.5 million through a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, exercised stock options and subsequently sold an equivalent number of shares on July 7, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, sold 2,000 shares of common stock for $52.88 per share on July 1, 2025, as part of a pre-arranged 10b5-1 trading plan.

Akero Therapeutics' Chief Development Officer, Catriona Yale, acquired 890 shares of common stock through the company's Employee Stock Purchase Plan.

Akero Therapeutics' Chief Operating Officer, Jonathan Young, reported a pre-planned acquisition of 890 shares of common stock at $23.868 per share, scheduled for June 30, 2025, through the company's Employee Stock Purchase Plan.

Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, acquired 193 shares of common stock at $23.868 per share through the company's Employee Stock Purchase Plan.

Akero Therapeutics' Chief Financial Officer, William Richard White, acquired 890 shares of common stock at a discounted price through the company's Employee Stock Purchase Plan.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, acquired 890 shares of common stock through the company's Employee Stock Purchase Plan.

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, acquired 299 shares of common stock at a discounted price through the company's Employee Stock Purchase Plan.

Akero Therapeutics' President and CEO, Andrew Cheng, acquired 890 shares of common stock at $23.868 per share through the company's Employee Stock Purchase Plan, increasing his direct beneficial ownership to 550,757 shares.

Akero Therapeutics, Inc. President and CEO Andrew Cheng sold 6,620 shares of common stock for tax withholding purposes at a weighted-average price of $54.84 per share.

Akero Therapeutics' Chief Technology Officer, Scott A. Gangloff, sold 848 shares of common stock for tax withholding purposes related to restricted stock unit vesting.

Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, sold 875 shares of common stock for $54.59 per share to cover tax withholding obligations related to restricted stock unit vesting.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, reported the sale of 1,129 shares of common stock at a weighted-average price of $54.84 to cover tax withholding obligations.

Akero Therapeutics, Inc.'s Chief Financial Officer, William Richard White, sold 1,634 shares of common stock in a non-discretionary transaction to cover tax withholding obligations.

Akero Therapeutics' Chief Development Officer, Catriona Yale, sold 1,633 shares of common stock at a weighted-average price of $54.84 to cover tax withholding obligations related to restricted stock unit vesting.

Akero Therapeutics Chief Operating Officer Jonathan Young sold 1,453 shares of common stock at a weighted-average price of $54.84 to satisfy tax withholding obligations related to restricted stock unit vesting.

Akero Therapeutics' Chief Development Officer, Catriona Yale, exercised stock options and subsequently sold an equivalent number of shares under a pre-arranged Rule 10b5-1 trading plan.

Akero Therapeutics' Senior VP of Commercial Strategy, Patrick Lamy, exercised stock options and subsequently sold a portion of the acquired shares on June 16, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Akero Therapeutics, Inc. President and CEO, Andrew Cheng, reported the sale of 37,837 shares of common stock on June 10, 2025, primarily through a Rule 10b5-1 trading plan and for tax withholding purposes.

Akero Therapeutics' Chief Scientific Officer, Timothy Rolph, sold 2,358 shares of common stock for approximately $53.996 per share to cover tax withholding obligations related to RSU vesting.

Akero Therapeutics' Chief Financial Officer, William Richard White, sold 2,804 shares of common stock for approximately $53.995 per share to cover tax withholding obligations related to restricted stock unit vesting.